Stoke Therapeutics, Inc. Deferred Costs, Current
Stoke Therapeutics, Inc. (STOK) had Deferred Costs, Current of $402.00 thousand as of 2024-03-31, per its 10-Q filed 2024-05-06.
Discontinued › Balance Sheet
us-gaap:DeferredCostsCurrent · last filed 2024-05-06
- 2024-03-31: Deferred Costs, Current $402.00K.
| Period end | Deferred Costs, Current |
|---|---|
| 2024-03-31 | $402.00K 10-Q · filed 2024-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |